Cover Image
市場調查報告書

Hybrigenics S.A.的產品平台分析

Hybrigenics S.A. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 259395
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Hybrigenics S.A.的產品平台分析 Hybrigenics S.A. - Product Pipeline Review - 2014
出版日期: 2014年12月24日 內容資訊: 英文 28 Pages
簡介

Hybrigenics S.A.是總公司設立於法國的生物科技企業,正在從事增生性癌症或非癌症性疾病之新標的及治療藥的研究開發。產品候補有作為維他命D受體的inecalcitol,適應症有前列腺癌,慢性淋巴性白血病,中重度的乾癬等。

本報告提供Hybrigenics S.A. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Hybrigenics S.A. 的基本資料

  • Hybrigenics S.A. 概要
  • 主要資訊
  • 企業資料

Hybrigenics S.A. :R&D概要

  • 主要的治療範圍

Hybrigenics S.A. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Hybrigenics S.A. :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • IND/CTA申請階段的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Hybrigenics S.A. :藥物簡介

  • inecalcitol
  • Small Molecules to Inhibit Deubiquitinating Enzymes
  • Small Molecules to Inhibit USP8 for Cancer

Hybrigenics S.A. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hybrigenics S.A. :最新的開發平台資訊

Hybrigenics S.A. :開發暫停中的計劃

Hybrigenics S.A. :企業理念

Hybrigenics S.A. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06709CDB

Summary

Global Markets Direct's, 'Hybrigenics S.A. - Product Pipeline Review - 2014', provides an overview of the Hybrigenics S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hybrigenics S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hybrigenics S.A. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hybrigenics S.A.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hybrigenics S.A.'s pipeline products

Reasons to buy

  • Evaluate Hybrigenics S.A.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hybrigenics S.A. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hybrigenics S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hybrigenics S.A. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hybrigenics S.A.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hybrigenics S.A. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hybrigenics S.A. Snapshot
    • Hybrigenics S.A. Overview
    • Key Information
    • Key Facts
  • Hybrigenics S.A. - Research and Development Overview
    • Key Therapeutic Areas
  • Hybrigenics S.A. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Hybrigenics S.A. - Pipeline Products Glance
    • Hybrigenics S.A. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Hybrigenics S.A. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Hybrigenics S.A. - Drug Profiles
    • inecalcitol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Deubiquitinating Enzymes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit USP8 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hybrigenics S.A. - Pipeline Analysis
    • Hybrigenics S.A. - Pipeline Products by Target
    • Hybrigenics S.A. - Pipeline Products by Route of Administration
    • Hybrigenics S.A. - Pipeline Products by Molecule Type
    • Hybrigenics S.A. - Pipeline Products by Mechanism of Action
  • Hybrigenics S.A. - Recent Pipeline Updates
  • Hybrigenics S.A. - Dormant Projects
  • Hybrigenics S.A. - Company Statement
  • Hybrigenics S.A. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hybrigenics S.A., Key Information
  • Hybrigenics S.A., Key Facts
  • Hybrigenics S.A. - Pipeline by Indication, 2014
  • Hybrigenics S.A. - Pipeline by Stage of Development, 2014
  • Hybrigenics S.A. - Monotherapy Products in Pipeline, 2014
  • Hybrigenics S.A. - Phase II, 2014
  • Hybrigenics S.A. - IND/CTA Filed, 2014
  • Hybrigenics S.A. - Preclinical, 2014
  • Hybrigenics S.A. - Discovery, 2014
  • Hybrigenics S.A. - Pipeline by Target, 2014
  • Hybrigenics S.A. - Pipeline by Route of Administration, 2014
  • Hybrigenics S.A. - Pipeline by Molecule Type, 2014
  • Hybrigenics S.A. - Pipeline Products by Mechanism of Action, 2014
  • Hybrigenics S.A. - Recent Pipeline Updates, 2014
  • Hybrigenics S.A. - Dormant Developmental Projects,2014
  • Hybrigenics S.A., Subsidiaries

List of Figures

  • Hybrigenics S.A. - Pipeline by Top 10 Indication, 2014
  • Hybrigenics S.A. - Pipeline by Stage of Development, 2014
  • Hybrigenics S.A. - Monotherapy Products in Pipeline, 2014
  • Hybrigenics S.A. - Pipeline by Top 10 Target, 2014
  • Hybrigenics S.A. - Pipeline by Top 10 Route of Administration, 2014
  • Hybrigenics S.A. - Pipeline by Top 10 Molecule Type, 2014
  • Hybrigenics S.A. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top